secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2024-11-01T23:59:59+00:00
Accession:  0001753926-24-001793
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella announces 1-for-8 reverse split effective Nov 7 to meet Nasdaq bid price
--------------------------------------------------------------------------------

- Reverse stock split ratio of 1-for-8; effective 5:00 p.m. ET on November 7, 2024.
- Common stock begins trading split-adjusted on November 8, 2024 under symbol LIPO.
- Authorized shares unchanged at 200,000,000; par value remains $0.0001 per share.
- Split intended to bring company into compliance with Nasdaq minimum bid price requirement.
- Approved by stockholders at Annual Meeting on September 10, 2024; CUSIP changes to 53630L209.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392624001793/0001753926-24-001793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392624001793/g084523_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer